Winston-Salem, N.C., June 16, 2012 – KeraNetics LLC announced today that it has been awarded a sub-contract on a $2 million dollar project from the U.S. Army’s Defense Medical Research and Development Program (DMRDP), part of the Congressionally Directed Medical Research Program. This contract is to develop and test keratin drug-delivery systems for a novel class of antibiotics. “Antibiotic resistance is an increasing problem for both military and civilian patients. This project will test a novel class of antibiotics that are not susceptible to drug resistance. Coupled with our keratin drug-delivery system, these compounds will prevent infections while speeding healing in wounds commonly seen on the battlefield,” said Dr. Luke Burnett, Senior Scientist and Co-Investigator for the project.
Dr. Burnett, Director of Product Development and Research for the Company, said “This project will leverage the strength of industry and government collaborations and could result in infection control products that change the Standard of Care for our Wounded Warriors. We are grateful to the U.S. Army for the opportunity to conduct this research.”